Catheterization and Cardiovascular Interventions
Volume 97, Issue 6 pp. 1160-1161
EDITORIAL COMMENT

GRACEfully assessing the timeline for noninfarct-related artery intervention in ST-elevation myocardial infarction patients

Jay Shah MD, 

Corresponding Author

Jay Shah MD

Division of Cardiology, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA

Correspondence

Jay Shah, Division of Cardiology, Lahey Hospital and Medical Center, Burlington, MA.

Email: [email protected]

Search for more papers by this author
Michael S. Levy MD, MPH, 

Michael S. Levy MD, MPH

Division of Cardiology, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA

Search for more papers by this author
First published: 11 May 2021
https://doi.org/10.1002/ccd.29719
Expert Article Analysis for: Benefit of a staged in-hospital revascularization strategy in hemodynamically stable patients with ST-segment elevation myocardial infarction and multivessel disease: Analyses by risk stratification

Key Points

  • A large registry study of ST-elevation myocardial infarction (STEMI) patients with multivessel disease and without cardiogenic shock demonstrated that staged in-hospital intervention of the noninfarct-related artery was associated with a reduced risk of all-cause mortality when compared to culprit-only PCI or immediate multivessel intervention.
  • A subgroup analysis stratified by the Global Registry of Acute Coronary Events (GRACE) score, showed a mortality benefit in high-risk patients (GRACE score > 140) undergoing staged in-hospital intervention of the noninfarct-related artery with a median interval between the two procedures of 5 days.
  • Further large, randomized trials are needed to help clarify appropriate timing for nonculprit staged intervention in STEMI patients.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.